NOVARTIS
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.
- Conditions
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 330
- Registration Number
- NCT01023815
- Locations
- 🇮🇹
Novartis Investigative Site, Vicenza, Italy
🇮🇹Novartis InvestigativeSite, Udine, Italy
🇮🇹Novarits Investigative Site, Pisa, Italy
A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo
- Conditions
- Interventions
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2012-04-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1324
- Registration Number
- NCT01005901
- Locations
- 🇹🇷
Novartis Investigative Site, Yenisehir/Izmir, Turkey
🇰🇷Novartis Investigative site, Seoul, Korea, Republic of
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2009-10-26
- Last Posted Date
- 2011-05-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 932
- Registration Number
- NCT01001572
- Locations
Investigative site in Romainia
Novartis Investigative Site
Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2012-10-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 396
- Registration Number
- NCT00989989
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
🇨🇳Novartis Investigational Site, Shanghai, China
Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 260
- Registration Number
- NCT00986414
- Locations
- 🇨🇦
Toronto Western Hospital, UHN, Toronto, Canada
🇪🇸Novartis Investigative Site, San Sebastian, Spain
🇦🇺Novartis Investigational Site, Westmead, Australia
To Evaluate the Safety, Tolerability and Analgesic Efficacy of SAF312 in Postoperative Dental Pain Patients
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 183
- Registration Number
- NCT00986882
- Locations
- 🇺🇸
Jean Brown Research, Salt Lake City, Utah, United States
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 2719
- Registration Number
- NCT00973349
- Locations
- 🇺🇸
Triangle Medical Research Associates, Raleigh, North Carolina, United States
🇺🇸PI Coor Clinical Research, Fairfax, Virginia, United States
🇺🇸Regional Clinical Research, Endwell, New York, United States
Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects
- Conditions
- Interventions
- First Posted Date
- 2009-08-11
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 126
- Registration Number
- NCT00956449
- Locations
- 🇬🇧
The Health Centre, Suffolk, United Kingdom
To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients
- First Posted Date
- 2009-08-11
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 21
- Registration Number
- NCT00956410
- Locations
- 🇬🇧
Novartis Investigative Site, Southampton, United Kingdom
Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010
- Conditions
- Interventions
- First Posted Date
- 2009-08-11
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 63
- Registration Number
- NCT00956761
- Locations
- 🇮🇹
Site 2: Ufficio Igiene e Sanità Pubblica di Lanciano, ASL Lanciano - Vasto, sede legale Via S. Spaventa, 37, Lanciano, Italy
🇮🇹Site 3: Pianiga Distretto n. 2 - Area Sud - Azienda ULSS 13 Mirano-Via Nazionale 48, Pianiga, Italy